Definitive Contract HHSO100200800059C
Award Date
9/16/08
Potential Completion Date
10/15/10
Potential Value
$22M
Awardee
Cleveland Biolabs, Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Buffalo, NY 14203, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
13
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award by the Department of Health and Human Services (HHS) to Cleveland Biolabs, Inc., a small business, under the Small Business Innovation Research (SBIR) program. The contract is for the development of "RADIOPROTECTORS TARGETING P53" and has a potential value of $1,499,998.00. The contract is a cost-plus-fixed-fee definitive contract with a period of performance ending on August 31, 2008. The place of performance is Cleveland, Ohio. This contract award...
This is a cost-plus-fixed-fee definitive contract awarded by the Defense Health Agency, a defense agency, to Cleveland Biolabs, Inc. The contract has a ceiling value of $3,558,603.15 and a period of performance through August 31, 2020. The contract was not set aside for any socioeconomic program. The purpose of the contract is not explicitly stated, but based on the agency and the location of performance in Buffalo, New York, it likely involves research and development or support services...
This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...
This is a $100,361,311 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to the non-profit research organization MRIGlobal, also known as Midwest Research Institute, for the development of "Biodosimetry High-Throughput Diagnostic Tests." The contract supports the creation of diagnostic tests to evaluate radiation exposure, which is a critical capability for public health emergency preparedness. As a prime contractor,...
This is a Firm Fixed Price (FFP) contract awarded by the U.S. Army Medical Command (MEDCOM) to Technology Holding LLC, a small business, for a Small Business Innovation Research (SBIR) Phase II project titled "Novel Biologic Countermeasure for Acute Radiation Syndrome." The contract has a ceiling value of $2,999,993.84 and a period of performance from June 2022 to October 2025. The R&D effort is focused on developing a novel biologic countermeasure to address acute radiation...
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025. The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Chrysalis Biotherapeutics, Inc. The contract is for "A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION" and has a ceiling value of $6,954,508.60. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and has an ultimate completion date of August 31, 2021. The...
This is a federal contract award to Partner Therapeutics, Inc., a biopharmaceutical company based in Lexington, Massachusetts, to provide a colony stimulating factor (G-CSF or GM-CSF) as a medical countermeasure for treating neutropenia arising from exposure to ionizing radiation. The contract, awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), has a ceiling value of $37,626,711.32 and an ultimate completion...
This is a $226,309,811.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Hopo Therapeutics, Inc. for the development of HOPO-101 as a medical countermeasure (MCM) decorporation agent to treat individuals with internal contamination from radionuclides and/or toxic heavy metals. The contract has an ultimate completion date of September 30, 2029 and was awarded on September 30, 2024 with no...